Japan Fortnightly Update: Lower Low as Earnings Slow
LOWER LOW - Japanese equities reached a new 52-week low on 29th October but rebounded on the subsequent four trading days to close the...
537 Views
Japan: The Demise of The "J Nifty-Fifty"?
THE J 'NIFTY-FIFTY' - In our insight posted on July 1st Japan: Most Overbought & Most Oversold - The Relative Price Score, we highlighted the...
614 Views
Chugai 3Q FY18 (YE Dec'18) Results - First Glance
Key highlights Continued brisk export of Actemra (+10.8% to ¥19.5b) and Alecensa (+95.7% to ¥9.2b) to Roche drove Chugai’s 3Q FY18e sales (+4.8% to...
523 Views
As Expected, USFDA Approves Hemlibra for Hemophilia A in Patients Without Inhibitors
Non-inhibitor patients constitute ~80-90% of the total hemophilia A population size Consequently, Hemlibra’s (emicizumab, in-house, US Launch -Nov...
443 Views
6-Months Looks to Be the Sweet Spot for Mean Revision in Japan....
It is no surprise to most that Japan is a mean-reverting market. Very few names experience long-term price runs like we see in other market. We...
487 Views